Accuracy of mammography dosimetry in the era of the European Directive 2013/59/Euratom transposition.


Journal

European journal of radiology
ISSN: 1872-7727
Titre abrégé: Eur J Radiol
Pays: Ireland
ID NLM: 8106411

Informations de publication

Date de publication:
Jun 2020
Historique:
received: 24 10 2019
revised: 30 01 2020
accepted: 28 03 2020
pubmed: 17 4 2020
medline: 8 1 2021
entrez: 17 4 2020
Statut: ppublish

Résumé

To evaluate the impact of increasing levels of accuracy for mean glandular dose (MGD) evaluation in the era of the European Directive 2013/59/Euratom transposition. 4028 women who had a mammography examination by one of five mammography units using different detector technologies were included in this study. 16,006 images were processed by a software algorithm that determines breast glandularity quantitatively and uses this to estimate patient-specific MGD (psMGD). Entrance dose (ED) values and half value layers (HVLs) measured for each mammography system were collected to evaluate the effect of equipment calibration in psMGD calculation. The psMGD values adjusted for system calibration were compared with organ dose (OD) provided by manufacturers as image metadata. Overall median relative difference between calibrated psMGD and organ dose was below 3%, with larger differences for individual systems. The psMGD adjustment for system calibration was particularly useful for one system for which ED had an evident miscalibration issue. The mean difference between psMGD with calibration and organ dose provided by manufacturers was 4.1 %, ranging from -16.3 % to +24.5 %. The proportion of images for which organ dose was more than 10 % 'inaccurate' compared to psMGD was between 11 % and 46 %, depending on the mammography system. Patient-specific mean glandular dose, possibly adjusted for system calibration, allows more accurate individual breast dosimetry than what would be performed using organ dose provided by manufacturers. Conversely, definition of diagnostic reference levels could be achieved using either psMGD or organ dose.

Identifiants

pubmed: 32298958
pii: S0720-048X(20)30175-3
doi: 10.1016/j.ejrad.2020.108986
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

108986

Commentaires et corrections

Type : CommentIn
Type : CommentIn

Informations de copyright

Copyright © 2020 Elsevier B.V. All rights reserved.

Auteurs

Gisella Gennaro (G)

Veneto Institute of Oncology IOV - IRCCS, Padua, Italy. Electronic address: gisella.gennaro@iov.veneto.it.

Sofia Bigolaro (S)

Veneto Institute of Oncology IOV - IRCCS, Padua, Italy.

Melissa L Hill (ML)

Volpara Health Technologies Ltd., Wellington, New Zealand.

Roberto Stramare (R)

University of Padua, Padua, Italy.

Francesca Caumo (F)

Veneto Institute of Oncology IOV - IRCCS, Padua, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH